05.21.26 -- AI Stuck Upstream? It Still Influences Manufacturing Outsourcing

Real‑world lessons for planning and executing tech transfers, with practical insights on early alignment, process readiness, risk reduction, and cross‑functional coordination for smoother scale‑up.

Onshoring biomanufacturing operations is an increasingly common decision. While a mid-phase tech transfer from international to domestic CDMO can be complex, the right partner can ensure success.

Experienced outsourcing partners will have the right facility and technical capabilities, a culture of speed and execution, and shared expectations and commitment to continuous improvement.

For emerging biotechs looking to refine their development processes and boost their chances of commercial success, exploring these partnership opportunities could prove invaluable.

Thorough characterization is key to unlocking the potential of antibody-based therapeutics. Leveraging a CDMO's extensive capabilities and expertise can allow you to navigate biopharmaceutical development.

Proper formulation development has a huge impact on whether a technology transfer to clinical phase fill/finish is successful. Review the challenges of transitioning a promising drug candidate.

Uncover the challenges when moving a bioconjugate candidate from early development to clinic, along with integrated solutions for navigating this growing area of the biopharmaceutical industry.

FDA rejection letters show common CCIT gaps — low sensitivity and incomplete validation. Spotting these trends helps teams strengthen integrity testing and avoid approval delays.

High particle counts don’t always mean high risk. Identifying particle type and origin—not just quantity—avoids false alarms, protects timelines, and turns data into action.

Selecting the right biologics CDMO requires evaluating technical depth, scalability, quality systems, and partnership fit to reduce risk and support long‑term development success.

Controlled nucleation standardizes freezing across all vials, leading to uniform ice crystals and improved lyo cake quality. This critical step reduces variability and supports robust product scale-up.

See three flexible Optima fill‑finish and syringe assembly systems to boost performance, accuracy, and scalability, enabling efficient processing of diverse formats and supporting rapid CDMO growth.

An advanced approach leveraging artificial intelligence identifies the root causes of aggregation, streamlining formulation development and ensuring consistent product quality.

Modern drug manufacturing requires a shift toward partnerships that prioritize agility and quality. Success depends on specialized expertise and technical collaboration to navigate requirements.

As demand for GLP-1s and biologics accelerates and timelines compress, it's crucial that pharmaceutical companies stay competitive and bring therapies to market by partnering with a CDMO.

See innovative process and facility models that optimize efficiency, sustainability, and cost-effectiveness in biopharmaceutical manufacturing.

Explore a solution for biopharmaceutical companies concerned about the risks an increase in campaign volume can pose to their production timeline.